Vivos Therapeutics, Inc. Revenue 2019–2025
Vivos Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2019 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Vivos Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 5.1 M, a 70.46% increase year-over-year.
- Vivos Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 18.8 M, a 28.19% increase year-over-year.
- Vivos Therapeutics, Inc. annual revenue for 2025 was 17.4 M, a 16.05% increase from 2024.
- Vivos Therapeutics, Inc. annual revenue for 2024 was 15.0 M, a 8.91% increase from 2023.
- Vivos Therapeutics, Inc. annual revenue for 2023 was 13.8 M, a 13.87% decrease from 2022.
- Vivos Therapeutics, Inc. annual revenue for 2022 was 16.0 M.
Vivos Therapeutics, Inc. (VVOS) — Frequently Asked Questions
Vivos Therapeutics, Inc. (VVOS) is a publicly traded US company. It has a market capitalization of $7M. In fiscal 2025 it reported revenue of $17M and net income of -$21M. Explore VVOS's stock price, financial statements, earnings history, margins and key ratios below.
What is Vivos Therapeutics, Inc.'s market cap?
Vivos Therapeutics, Inc. (VVOS) has a market capitalization of $7M.
What is the VVOS stock price?
VVOS trades at $0.64 (-8.73% on the day).
How much revenue does Vivos Therapeutics, Inc. make?
Vivos Therapeutics, Inc. reported revenue of $17M in fiscal 2025.
Is VVOS profitable?
In fiscal 2025, Vivos Therapeutics, Inc. reported net income of -$21M.